LineaGen, Inc

Salt Lake City, UT · Founded 2006 · CIK 0001415979 · Biotech · Acquired

Clinical genetic testing and analysis platform for identifying genetic causes of neurodevelopmental disorders

bionanolaboratories.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$38M
6 Form D · Jan 2015
140 months since last filing
Contracts
—
No federal contracts on record
Patents
32
0 granted · 32 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,100,000
Private capital raisedForm D · SEC$5,012,787
Private capital raisedForm D · SEC$3,600,000
Private capital raisedForm D · SEC$150,000
Private capital raisedForm D · SEC$16,107,915
Private capital raisedForm D · SEC$12,173,420
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2262HEMATHERIX LLC——
2263TACIT THERAPEUTICS, INC.——
2264SOTERIA SYSTEMS, INC.—$2.7M
2265LineaGen, Inc—$38M
2266GPER G-1 Development Group LLC——
2267VIROGENICS, INC.——
2268PRODIGY BIOTECH, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 15 related persons
  • Burt De MillExecutive Officer
  • Lisa DunleaDirector
  • Michael FitzgeraldDirector
  • Al HarrisDirector
  • Michael JerstadDirector
  • David KabakoffDirector
  • Fred MiddletonDirector
  • Gayland MoffatExecutive Officer
  • Dinesh PatelDirector
  • Michael PaulDirector · Executive Officer
  • Stephen PrescottDirector
  • Mary TannerDirector
  • Michael WalshDirector
  • Marc WhiteExecutive Officer
  • Daniel WoodDirector

Patents

USPTO · 0 granted of 32
  • Genetic Markers Associated With Asd And Other Childhood Developmental Delay Disordersapplication
  • Genetic Markers Associated With Asd And Other Childhood Developmental Delay Disordersapplication
  • Diagnosis And Prediction Of Autism Spectrum Disorderapplication
  • Identification Of Seizure Susceptibility Region In Wolf-hirschhorn Syndrome And Treatment Thereofapplication
  • Genetic Markers Associated With Asd And Other Childhood Developmental Delay Disordersapplication
  • Diagnosis And Prediction Of Autism Spectrum Disorderapplication
  • Identification Of Seizure Susceptibility Region In Wolf-hirschhorn Syndrome And Treatment Thereofapplication
  • Apparatus, Compositions, and Methods for Assessment of Chronic Obstructive Pulmonary Disease Progression Among Rapid and Slow Decline Conditionsapplication
  • Risk Factors of Cigarette Smoke-Induced Spriometric Phenotypesapplication
  • Methods For Identification And Prediction Of Multiple Sclerosis Disease And Therapy Responseapplication
  • Diagnosis And Prediction Of Autism Spectrum Disorderapplication
  • Genetic Markers Associated With Asd And Other Childhood Developmental Delay Disordersapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.